The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, MEI Pharma's share price is $3.05.
MEI Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $10.90. Hence, MEI Pharma's PS Ratio for today is 0.28.
Good Sign:
MEI Pharma Inc stock PS Ratio (=0.28) is close to 10-year low of 0.28
The historical rank and industry rank for MEI Pharma's PS Ratio or its related term are showing as below:
MEIP'
s PS Ratio Range Over the Past 10 Years
Min: 0.27 Med: 8.52 Max: 121.62
Current: 0.28
During the past 13 years, MEI Pharma's highest PS Ratio was 121.62. The lowest was 0.27. And the median was 8.52.
MEIP's PS Ratio is ranked better than 97.89% of 993
companies
in the Biotechnology industry
Industry Median: 8.92
vs MEIP: 0.28
MEI Pharma Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of MEI Pharma was 16.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 6.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 57.40% per year.
During the past 13 years, MEI Pharma's highest 3-Year average Revenue per Share Growth Rate was 237.10% per year. The lowest was -21.50% per year. And the median was 42.60% per year.
Back to Basics: PS Ratio
MEI Pharma PS Ratio Historical Data
The historical data trend for MEI Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MEI Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEI Pharma's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MEI Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where MEI Pharma's PS Ratio falls into.
MEI Pharma PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
MEI Pharma's Share Price of today is $3.05. MEI Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.90.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
MEI Pharma PS Ratio Related Terms
Thank you for viewing the detailed overview of MEI Pharma's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEIP has been successfully added to your 